Music |
Video |
Movies |
Chart |
Show |
Examining Issues Surrounding Initiation and Discontinuation of Ibrutinib (OncLive) View | |
Second-Line Options in CLL: Progressing on Ibrutinib (Targeted Oncology) View | |
Case 1: Targeted Therapy: Ibrutinib for Newly Diagnosed CLL (Targeted Oncology) View | |
Understanding ultra high-risk CLL and advances with Ibrutinib (EMJ) View | |
Ibrutinib as a frontline therapy in RESONATE2 trials for CLL (ecancer) View | |
ASH12: Experimental Ibrutinib Promotes High Response Rate in Leukemia (MDedge: news and insights for busy physicians) View | |
Combining and Sequencing New Agents in Chronic Lymphocytic Leukemia (OncLive) View | |
Bcl-2 Inhibition With ABT-199 in CLL, Lymphomas (OncLive) View | |
Ibrutinib, Bruton’s tyrosine kinase inhibitor, for non-Hodgkin lymphoma (VJHemOnc – Video Journal of Hematology \u0026 HemOnc) View | |
ASCO 2015: New Ibrutinib Combination Regimen Shows Substantial Benefits in Relapsed CLL (EMJ) View |